Guardian Pharmacy Services, Inc.(GRDN)Earnings, Financials & Key Ratios

GRDN•NYSE

$36.58

$2.32B mkt cap·46.9× P/E·Price updated May 6, 2026

SectorHealthcare IndustryMedical Distribution Sub-IndustryPharmacy and Long-Term Care Services

AboutGuardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.Show more

Revenue$1.45B+17.9%
EBITDA$111M+357.8%
Net Income$49M+156.4%
EPS (Diluted)0.78+144.1%
Gross Margin19.47%-2.1%
EBITDA Margin7.68%+318.6%
Operating Margin6.14%+219.8%
Net Margin3.4%+147.8%
ROE26.76%+132.2%
ROIC35.13%+215.7%
Debt/Equity0.21-17.6%
Interest Coverage133.71+793.5%

Technical→

GRDN Key Insights

Guardian Pharmacy Services, Inc. (GRDN) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Strong 5Y profit CAGR of 19.8%
✓Momentum leader: RS Rating 80 (top 20%)
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 14.5%
✓Efficient asset utilization: 3.5x turnover

✗Weaknesses

✗Thin 5Y average net margin of 0.9%
✗Expensive at 10.6x book value

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

GRDN Price & Volume

Guardian Pharmacy Services, Inc. (GRDN) stock price & volume — 10-year historical chart

Loading chart...

GRDN Growth Metrics

Guardian Pharmacy Services, Inc. (GRDN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years14.5%

3 Years16.81%

TTM13.54%

Profit CAGR

10 Years-

5 Years19.8%

3 Years11.59%

TTM165.82%

EPS CAGR

10 Years-

5 Years18.77%

3 Years10.38%

TTM156.08%

Return on Capital

10 Years21.57%

5 Years18.54%

3 Years10.14%

Last Year41.49%

GRDN Recent Earnings

Guardian Pharmacy Services, Inc. (GRDN) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 4/12 qtrs (67%)●Beat Revenue 4/12 qtrs (67%)

Q2 2026Latest

Mar 11, 2026

EPS

$0.37

Est $0.27

+37.0%

Revenue

$398M

Est $390M

+1.9%

Q4 2025

Nov 10, 2025

EPS

$0.25

Est $0.24

+4.2%

Revenue

$377M

Est $390M

-3.2%

Q3 2025

Aug 11, 2025

EPS

$0.23

Est $0.22

+4.5%

Revenue

$344M

Est $344M

+0.1%

Q2 2025

May 12, 2025

EPS

$0.21

Est $0.22

-4.5%

Revenue

$329M

Est $329M

-0.0%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	Mar 11, 2026	$0.37vs $0.27+37.0%	$398Mvs $390M+1.9%
Q4 2025	Nov 10, 2025	$0.25vs $0.24+4.2%	$377Mvs $390M-3.2%
Q3 2025	Aug 11, 2025	$0.23vs $0.22+4.5%	$344Mvs $344M+0.1%
Q2 2025	May 12, 2025	$0.21vs $0.22-4.5%	$329Mvs $329M-0.0%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	Debt / Equity
OMCLOmnicell, Inc.Direct Competitor	1.99B	43.76	987.81	6.53%	1.67%	1.64%	0.17
PINCPremier, Inc.Direct Competitor	2.34B	28.26	128.45	-10.86%	-2.42%	-1.59%	0.18
CVSCVS Health CorporationProduct Competitor	111.32B	86.86	62.49	7.85%	0.72%	3.86%	1.24
CCRNCross Country Healthcare, Inc.Product Competitor	326.32M	10.11	-3.45	-21.56%	-9%	-24.3%	0.01
MCKMcKesson CorporationSupply Chain	91.09B	743.67	28.91	16.22%	1.09%
CAHCardinal Health, Inc.Supply Chain	45.06B	191.49	29.69	-1.87%	0.62%
VEEVVeeva Systems Inc.Supply Chain	27.2B	167.29	30.75	16.34%	28.44%	13.41%	0.01
ENSGThe Ensign Group, Inc.Often Compared	10.28B	175.93	30.13	18.72%	6.89%	16.61%	1.86

Compare GRDN vs Peers

Guardian Pharmacy Services, Inc. (GRDN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs OMCL

Most directly comparable listed peer for GRDN.

Scale Benchmark

vs CVS

Larger-name benchmark to compare GRDN against a more recognizable public peer.

Peer Set

Compare Top 5

vs OMCL, PINC, CVS, CCRN

GRDN Income Statement

Guardian Pharmacy Services, Inc. (GRDN) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Sales/Revenue	600.37M	698.29M	735.96M	792.07M	908.91M	1.05B	1.23B	1.45B	1.46B
Revenue Growth %	-	16.31%	5.39%	7.62%	14.75%	15.1%	17.42%	17.93%	13.54%
Cost of Goods Sold	477.33M	554.83M	588.96M	630.81M	723.04M	837.88M	984.04M	1.17B	1.16B
COGS % of Revenue	79.51%	79.46%	80.03%	79.64%	79.55%	80.09%	80.11%	80.53%	-
Gross Profit	123.03M▲ 0%	143.46M▲ 16.6%	147M▲ 2.5%	161.26M▲ 9.7%	185.87M▲ 15.3%	208.31M▲ 12.1%	244.37M▲ 17.3%	282.04M▲ 15.4%	294M▲ 0%
Gross Margin %	20.49%	20.54%	19.97%	20.36%	20.45%	19.91%	19.89%	19.47%	20.19%
Gross Profit Growth %	-	16.6%	2.47%	9.7%	15.25%	12.08%	17.31%	15.42%	-
Operating Expenses	97.1M	109.36M	114.94M	131.12M	133.88M	167.36M	307.29M	193.13M	200.42M
OpEx % of Revenue	16.17%	15.66%	15.62%	16.55%	14.73%	16%	25.02%	13.33%	-
Selling, General & Admin	87.84M	97.56M	102.54M	131.12M	133.88M	167.36M	307.29M	220.02M	227.31M
SG&A % of Revenue	14.63%	13.97%	13.93%	16.55%	14.73%	16%	25.02%	15.19%	-
Research & Development	0	0	0	0	0	0	0	0	0
R&D % of Revenue	-	-	-	-	-	-	-	-	-
Other Operating Expenses	9.26M	11.8M	12.4M	0	0	0	0	-26.89M	-1000K
Operating Income	25.93M▲ 0%	34.1M▲ 31.5%	32.06M▼ 6.0%	30.15M▼ 6.0%	51.99M▲ 72.4%	40.95M▼ 21.2%	-62.92M▼ 253.7%	88.91M▲ 241.3%	93.58M▲ 0%
Operating Margin %	4.32%	4.88%	4.36%	3.81%	5.72%	3.91%	-5.12%	6.14%	6.43%
Operating Income Growth %	-	31.5%	-5.97%	-5.97%	72.44%	-21.24%	-253.67%	241.31%	-
EBITDA	39.06M	49.95M	49.32M	46.68M	68.55M	59.18M	-43.15M	111.25M	111.63M
EBITDA Margin %	6.51%	7.15%	6.7%	5.89%	7.54%	5.66%	-3.51%	7.68%	7.67%
EBITDA Growth %	-	27.86%	-1.26%	-5.36%	46.86%	-13.67%	-172.91%	357.83%	362.5%
D&A (Non-Cash Add-back)	13.13M	15.85M	17.26M	16.53M	16.56M	18.23M	19.77M	22.34M	18.05M
EBIT	25.17M	33.62M	31.82M	29.96M	51.59M	40.58M	-63.2M	88.91M	66.15M
Net Interest Income	-1.9M	-2.25M	-2.16M	-1.64M	-1.93M	-2.86M	-3.28M	-665K	-495K
Interest Income	0	0	0	0	0	0	0	0	0
Interest Expense	1.9M	2.25M	2.16M	1.64M	1.93M	2.86M	3.28M	665K	649K
Other Income/Expense	-2.66M	-2.73M	-2.4M	-1.82M	-2.33M	-3.23M	-3.56M	-15.49M	-14.97M
Pretax Income	23.27M▲ 0%	31.37M▲ 34.8%	29.66M▼ 5.5%	28.33M▼ 4.5%	49.66M▲ 75.3%	37.72M▼ 24.0%	-66.48M▼ 276.2%	73.42M▲ 210.4%	78.61M▲ 0%
Pretax Margin %	3.88%	4.49%	4.03%	3.58%	5.46%	3.61%	-5.41%	5.07%	5.4%
Income Tax	0	0	0	0	0	0	4.56M	24.46M	25.38M
Effective Tax Rate %	0%	0%	0%	0%	0%	0%	-6.85%	33.32%	32.29%
Net Income	14.68M▲ 0%	21.75M▲ 48.1%	19.94M▼ 8.3%	16.31M▼ 18.2%	35.42M▲ 117.1%	23.9M▼ 32.5%	-87.29M▼ 465.2%	49.22M▲ 156.4%	53.07M▲ 0%
Net Margin %	2.44%	3.11%	2.71%	2.06%	3.9%	2.28%	-7.11%	3.4%	3.64%
Net Income Growth %	-	48.15%	-8.29%	-18.2%	117.12%	-32.52%	-465.19%	156.39%	165.82%
Net Income (Continuing)	23.27M	31.37M	29.66M	28.33M	49.66M	37.72M	-71.03M	48.96M	52.98M
Discontinued Operations	0	0	0	0	0	0	0	0	0
Minority Interest	25.86M	27.72M	28.59M	29.39M	33.2M	31.65M	7.3M	12.16M	11.53M
EPS (Diluted)	0.24▲ 0%	0.36▲ 50.0%	0.33▼ 8.3%	0.27▼ 18.2%	0.58▲ 114.8%	0.39▼ 32.8%	-1.77▼ 553.8%	0.78▲ 144.1%	0.83▲ 0%
EPS Growth %	-	50%	-8.33%	-18.18%	114.81%	-32.76%	-553.85%	144.07%	156.08%
EPS (Basic)	0.24	0.36	0.33	0.27	0.58	0.39	-1.77	0.79	-
Diluted Shares Outstanding	60.84M	60.84M	60.84M	60.84M	60.84M	60.84M	62.01M	63.3M	63.69M
Basic Shares Outstanding	60.84M	60.84M	60.84M	60.84M	60.84M	60.84M	62.01M	62.39M	63.32M
Dividend Payout Ratio	156.1%	114.56%	54.23%	106.39%	86.97%	160.75%	-	-	-

GRDN Balance Sheet

Guardian Pharmacy Services, Inc. (GRDN) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Total Current Assets	81.23M	90.08M	93.82M	111.87M	120M	129.6M	151.99M	221.63M	235.18M
Cash & Short-Term Investments	2.25M	275K	6.45M	15.01M	607K	752K	4.66M	65.62M	64.89M
Cash Only	2.25M	275K	6.45M	15.01M	607K	752K	4.66M	65.62M	64.89M
Short-Term Investments	0	0	0	0	0	0	0	0	0
Accounts Receivable	47.66M	54.21M	45.78M	55.25M	67.83M	77.26M	97.15M	101.61M	111.7M
Days Sales Outstanding	28.97	28.34	22.7	25.46	27.24	26.96	28.87	25.6	25.92
Inventory	27.54M	30.94M	31.93M	33.09M	41.44M	36.73M	40.55M	43.36M	47.16M
Days Inventory Outstanding	21.06	20.35	19.79	19.15	20.92	16	15.04	13.57	14.33
Other Current Assets	3.78M	4.66M	2.89M	8.52M	10.12M	14.86M	9.62M	11.04M	11.43M
Total Non-Current Assets	100.58M	106.43M	124.05M	123.98M	136.12M	141.56M	168.82M	191.02M	191.76M
Property, Plant & Equipment	27.98M	35.41M	51.98M	51.72M	65.19M	73.18M	78.96M	90.17M	90.89M
Fixed Asset Turnover	21.46x	19.72x	14.16x	15.31x	13.94x	14.30x	15.56x	16.07x	16.37x
Goodwill	47.82M	46.33M	52.45M	54.63M	56.05M	56.05M	69.3M	79.74M	79.74M
Intangible Assets	23.82M	20.69M	19.11M	17.09M	14.44M	11.98M	14.91M	18.48M	17.48M
Long-Term Investments	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	953K	4.01M	505K	529K	435K	358K	5.66M	436K	7.93M
Total Assets	181.81M▲ 0%	196.51M▲ 8.1%	217.87M▲ 10.9%	235.85M▲ 8.3%	256.11M▲ 8.6%	271.17M▲ 5.9%	320.81M▲ 18.3%	412.66M▲ 28.6%	426.94M▲ 0%
Asset Turnover	3.30x	3.55x	3.38x	3.36x	3.55x	3.86x	3.83x	3.51x	3.67x
Asset Growth %	-	8.09%	10.87%	8.25%	8.59%	5.88%	18.31%	28.63%	85.31%
Total Current Liabilities	65.27M	90.19M	86.35M	111.54M	112M	138.01M	144.12M	160.7M	160.54M
Accounts Payable	47.53M	54.93M	53.41M	64.62M	78.1M	85.6M	102.42M	116.21M	108.55M
Days Payables Outstanding	36.34	36.14	33.1	37.39	39.43	37.29	37.99	36.36	35.45
Short-Term Debt	2.64M	17.04M	3.63M	3.71M	7.96M	12.98M	0	7.15M	7.22M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0
Other Current Liabilities	7.68M	9.94M	0	20.42M	3.62M	12.33M	16.65M	30.2M	153.32M
Current Ratio	1.24x	1.00x	1.09x	1.00x	1.07x	0.94x	1.05x	1.38x	1.38x
Quick Ratio	0.82x	0.66x	0.72x	0.71x	0.70x	0.67x	0.77x	1.11x	1.11x
Cash Conversion Cycle	13.69	12.55	9.39	7.21	8.73	5.66	5.92	2.81	4.81
Total Non-Current Liabilities	48.53M	49.28M	64.44M	70.99M	68.18M	73.29M	26.71M	34.03M	33.97M
Long-Term Debt	36.37M	33.66M	30.74M	26.99M	22.97M	18.99M	0	0	0
Capital Lease Obligations	2.35M	3.59M	15.54M	16.12M	23.67M	27.04M	26.71M	33.69M	93.73M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	9.81M	12.03M	18.16M	27.88M	21.54M	27.26M	0	337K	39.53M
Total Liabilities	113.8M	139.47M	150.8M	182.53M	180.18M	211.31M	170.83M	194.73M	194.52M
Total Debt	43.71M	57.12M	58.84M	55.04M	62.98M	69.15M	37.33M	44.72M	7.22M
Net Debt	41.46M	56.84M	52.39M	40.03M	62.38M	68.4M	32.67M	-20.89M	-57.67M
Debt / Equity	0.64x	2.06x	0.88x	1.03x	0.83x	1.16x	0.25x	0.21x	0.21x
Debt / EBITDA	1.12x	1.14x	1.19x	1.18x	0.92x	1.17x	-	0.40x	0.06x
Net Debt / EBITDA	1.06x	1.14x	1.06x	0.86x	0.91x	1.16x	-	-0.19x	-0.19x
Interest Coverage	13.25x	14.94x	14.76x	18.30x	26.78x	14.19x	-19.28x	133.71x	101.92x
Total Equity	68.01M▲ 0%	27.72M▼ 59.2%	67.07M▲ 142.0%	53.32M▼ 20.5%	75.93M▲ 42.4%	59.86M▼ 21.2%	149.98M▲ 150.5%	217.92M▲ 45.3%	243.96M▲ 0%
Equity Growth %	-	-59.24%	141.97%	-20.5%	42.41%	-21.16%	150.55%	45.31%	354.82%
Book Value per Share	1.12	0.46	1.10	0.88	1.25	0.98	2.42	3.44	3.83
Total Shareholders' Equity	34.03M	0	38.48M	23.93M	42.73M	28.21M	142.67M	205.76M	232.42M
Common Stock	34.03M	29.95M	39.15M	24.11M	42.73M	28.21M	63K	63K	63K
Retained Earnings	0	0	0	0	0	0	17.12M	66.34M	79.64M
Treasury Stock	0	0	0	0	0	0	0	0	0
Accumulated OCI	-386K	-630K	-676K	-185K	0	0	0	0	0
Minority Interest	25.86M	27.72M	28.59M	29.39M	33.2M	31.65M	7.3M	12.16M	11.53M

GRDN Cash Flow Statement

Guardian Pharmacy Services, Inc. (GRDN) cash flow — operating, investing & free cash flow history

Line item	Dec'18	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25	TTM
Cash from Operations	43.67M	56.16M	52.61M	58.5M	48.52M	70.82M	57.96M	100.29M	100.29M
Operating CF Margin %	7.27%	8.04%	7.15%	7.39%	5.34%	6.77%	4.72%	6.92%	-
Operating CF Growth %	-	28.59%	-6.32%	11.19%	-17.05%	45.95%	-18.16%	73.04%	1359.58%
Net Income	23.27M	31.37M	29.66M	28.33M	49.66M	37.72M	-71.03M	49.22M	53.07M
Depreciation & Amortization	13.13M	15.85M	17.26M	16.53M	16.56M	18.23M	19.77M	22.34M	22.07M
Stock-Based Compensation	5.98M	1.93M	3.21M	13.03M	-3.38M	-6.09M	131.49M	13.85M	11.74M
Deferred Taxes	0	0	0	0	0	0	0	3.07M	3.07M
Other Non-Cash Items	2.95M	5.67M	3.58M	2.08M	4.4M	5.35M	7.14M	5.43M	-9.44M
Working Capital Changes	-1.66M	1.34M	-1.09M	-1.47M	-18.72M	15.6M	-29.41M	6.38M	8.1M
Change in Receivables	-8.79M	-11.13M	3.58M	-7.71M	-16.79M	-14.3M	-25.48M	-8.55M	-6.48M
Change in Inventory	475K	-3.05M	379K	-240K	-8.12M	4.43M	-1.15M	-877K	-1.8M
Change in Payables	9.05M	7.91M	-1.95M	9.78M	13.37M	6.29M	13.23M	16.4M	6.73M
Cash from Investing	-20.75M	-16.59M	-12.18M	-13.15M	-17.9M	-13.44M	-30.41M	-32.26M	-31.08M
Capital Expenditures	-10.01M	-14.54M	-8.34M	-9.28M	-16.77M	-14.56M	-16.37M	-19.58M	-28.31M
CapEx % of Revenue	1.67%	2.08%	1.13%	1.17%	1.85%	1.39%	1.33%	1.35%	-
Acquisitions	-10.68M	-2.07M	-4.38M	-4.4M	-2M	-985K	-14.71M	0	-4M
Investments	-	-	-	-	-	-	-	-	-
Other Investing	-57K	16K	545K	535K	874K	2.1M	671K	-12.68M	1.23M
Cash from Financing	-21.07M	-41.55M	-34.26M	-36.79M	-45.03M	-57.23M	-23.64M	-7.07M	-6.79M
Debt Issued (Net)	16.03M	2.3M	-13.37M	-6.1M	-2.8M	-2.89M	-36.48M	-4.98M	-3.85M
Equity Issued (Net)	0	0	0	0	0	0	64.61M	-1.59M	0
Dividends Paid	-27.99M	-34.32M	-10.82M	-17.36M	-30.8M	-38.42M	-35.75M	0	0
Share Repurchases	0	0	0	0	0	0	-55.18M	-29.04M	-59.31M
Other Financing	-9.11M	-9.52M	-10.07M	-13.34M	-11.42M	-15.92M	-16.02M	-497K	-2.95M
Net Change in Cash	1.85M▲ 0%	-1.98M▼ 206.8%	6.17M▲ 412.3%	8.56M▲ 38.7%	-14.4M▼ 268.2%	145K▲ 101.0%	3.91M▲ 2595.2%	60.96M▲ 1459.9%	50.89M▲ 0%
Free Cash Flow	33.67M▲ 0%	41.62M▲ 23.6%	44.27M▲ 6.4%	49.22M▲ 11.2%	31.75M▼ 35.5%	56.26M▲ 77.2%	41.59M▼ 26.1%	80.71M▲ 94.1%	70.01M▲ 0%
FCF Margin %	5.61%	5.96%	6.02%	6.21%	3.49%	5.38%	3.39%	5.57%	4.81%
FCF Growth %	-	23.63%	6.36%	11.17%	-35.48%	77.2%	-26.08%	94.05%	44.72%
FCF per Share	0.55	0.68	0.73	0.81	0.52	0.92	0.67	1.28	1.28
FCF Conversion (FCF/Net Income)	2.98x	2.58x	2.64x	3.59x	1.37x	2.96x	-0.66x	2.04x	1.32x
Interest Paid	1.83M	2.25M	2.08M	1.52M	1.78M	2.78M	3.12M	0	475K
Taxes Paid	0	0	0	0	0	0	0	0	6.84M

GRDN Key Ratios

Guardian Pharmacy Services, Inc. (GRDN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2019	2020	2021	2022	2023	2024	2025	TTM
Return on Equity (ROE)	45.43%	42.08%	27.1%	54.81%	35.2%	-83.2%	26.76%	25.36%
Return on Invested Capital (ROIC)	26.36%	23.57%	21.25%	33.66%	23.04%	-30.36%	35.13%	35.13%
Gross Margin	20.54%	19.97%	20.36%	20.45%	19.91%	19.89%	19.47%	20.19%
Net Margin	3.11%	2.71%	2.06%	3.9%	2.28%	-7.11%	3.4%	3.64%
Debt / Equity	2.06x	0.88x	1.03x	0.83x	1.16x	0.25x	0.21x	0.21x
Interest Coverage	14.94x	14.76x	18.30x	26.78x	14.19x	-19.28x	133.71x	101.92x
FCF Conversion	2.58x	2.64x	3.59x	1.37x	2.96x	-0.66x	2.04x	1.32x
Revenue Growth	16.31%	5.39%	7.62%	14.75%	15.1%	17.42%	17.93%	13.54%

GRDN SEC Filings & Documents

Guardian Pharmacy Services, Inc. (GRDN) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

May 6, 2026·SEC

Material company update

Mar 23, 2026·SEC

Material company update

Mar 11, 2026·SEC

10-K Annual Reports

FY 2026

Mar 11, 2026·SEC

FY 2025

Mar 26, 2025·SEC

10-Q Quarterly Reports

FY 2026

May 6, 2026·SEC

FY 2025

Nov 10, 2025·SEC

FY 2025

Aug 11, 2025·SEC

GRDN Frequently Asked Questions

Guardian Pharmacy Services, Inc. (GRDN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Guardian Pharmacy Services, Inc. (GRDN) reported $1.46B in revenue for fiscal year 2025. This represents a 143% increase from $600.4M in 2018.

Guardian Pharmacy Services, Inc. (GRDN) grew revenue by 17.9% over the past year. This is strong growth.

Yes, Guardian Pharmacy Services, Inc. (GRDN) is profitable, generating $53.1M in net income for fiscal year 2025 (3.4% net margin).

Dividend & Returns

Guardian Pharmacy Services, Inc. (GRDN) has a return on equity (ROE) of 26.8%. This is excellent, indicating efficient use of shareholder capital.

Guardian Pharmacy Services, Inc. (GRDN) generated $70.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More GRDN

Guardian Pharmacy Services, Inc. (GRDN) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

Guardian Pharmacy Services, Inc.(GRDN)Earnings, Financials & Key Ratios

GRDN Key Insights

✓Strengths

✗Weaknesses

GRDN Price & Volume

GRDN Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

GRDN Recent Earnings

GRDN Peer Comparison

Compare GRDN vs Peers

vs OMCL

vs CVS

Compare Top 5

GRDN Income Statement

GRDN Balance Sheet

GRDN Cash Flow Statement

GRDN Key Ratios

GRDN SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

GRDN Frequently Asked Questions

Explore More GRDN

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation